ArnoldA., ShatttuckT.M., MallyaS.M.. Molecular pathogenesis of primary hyperparathyroidism.J Bone Miner Res2002; (Suppl 2): S30–6.
2.
BrownE.M.Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue.J Clin Endocrinol Metab1983, 56: 572–81.
BilezikianJ.P., KhanA.A., PottsJ.T.Jr.. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.J Clin Endocrinol Metab2009; 94: 335–9.
5.
KhanA., GreyA., ShobackD.Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.J Clin Endocrinol Metab2009; 94: 373–81.
6.
SilverbergJ.P., ShaneE., JacobsT.P., SirisE.S., BilezikianJ.P.A ten-year prospective study of primary hyperparathyroidism with or without parathyroid surgery, N Engl J Med1999; 341: 1249–555.
7.
RubinM.R., BilezikianJ.P., McMahonD.J.. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.J Clin Endocrinol Metab2008; 93: 3462–70.
8.
Gazzetta Ufficiale del 01–10–2008, 230.
9.
ShobackD., BilezikianJ.P., TurnerS.A., McCaryL.C., GuoM.D., PeacockM.The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.J Endocrinol Metab2003; 88: 5644–9.
10.
PeacockM., BilezikianJ.P., KlassenP.S., GuoM.D., TurnerS.A., ShobackD.Cinacalcet hydrochoride maintains long-term normocalcemia in patients with primary hyperparathyroidism.J Clin Endocrinol Metab2005; 90: 35–41.
11.
PeacockM., ScumpiaS., BologneseM.A.. Long-term control of primary hyperparathyroidism with cinacalcet.J Bone Miner Res2006; 21(Suppl 1Il calciomimetico nell'iperparatiroidismo primitivo e se): S38.
12.
GreyA.B., StapletonJ.P., EvansM.C., TatnellM., ReidI.R.Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism.Ann Int Med1996; 125: 360–8.
13.
RubinM.R., LeeK.H., McMahonD.J., SilverbergS.J.Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism.J Clin Endocrinol Metab2003; 88: 1174–8.
14.
ZanchettaJ.R., BogadoC.Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.J Bone Miner Res2001; 1: 189–90.
15.
RossiniM., GattiD., IsaiaG., SartoriL., BragaV., AdamiS.Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.J Bone Miner Res2001; 16: 113–9.
16.
KhanA.A., Bilezikian JP, Kung AWC, et al. Alendronate in primary hyperparathyroidism: a doubleblind, randomized, placebo-controlled trial.J Endocrinol Metab2004; 89: 3319–25.
